Edinburgh Imaging's current multiple sclerosis projects. HTML Current projects Title Description CCMR1 A double-blind, randomised placebo-controlled study of the safety & tolerability of a retinoid-X receptor agonist’s ability to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease-modifying therapy: a phase 2a trial. Future MS To develop predictive tools for focal neuroinflammatory disease activity over 12-months based on baseline clinical, laboratory, & genomic assessment. Future MS 2 To investigate questions MS patients commonly ask their doctors about, including invisible disability symptoms like pain and fatigue. This article was published on Thursday 22 August 2024
HTML Current projects Title Description CCMR1 A double-blind, randomised placebo-controlled study of the safety & tolerability of a retinoid-X receptor agonist’s ability to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease-modifying therapy: a phase 2a trial. Future MS To develop predictive tools for focal neuroinflammatory disease activity over 12-months based on baseline clinical, laboratory, & genomic assessment. Future MS 2 To investigate questions MS patients commonly ask their doctors about, including invisible disability symptoms like pain and fatigue.
